Volume | 34,863 |
|
|||||
News | - | ||||||
Day High | 13.10 | Low High |
|||||
Day Low | 12.8901 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Skye Bioscience Inc | SKYE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
13.03 | 12.8901 | 13.10 | 13.02 | 12.99 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
605 | 34,863 | US$ 12.95 | US$ 451,547 | - | 11.11 - 17.6473 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:00:00 | 186 | US$ 13.00 | USD |
Skye Bioscience Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
US$ 365.38M | - | - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Skye Bioscience News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SKYE Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 13.00 | 13.51 | 12.52 | 12.93 | 32,268 | 0.02 | 0.15% |
1 Month | 13.50 | 17.6473 | 11.11 | 14.56 | 72,034 | -0.48 | -3.56% |
3 Months | 13.50 | 17.6473 | 11.11 | 14.56 | 72,034 | -0.48 | -3.56% |
6 Months | 13.50 | 17.6473 | 11.11 | 14.56 | 72,034 | -0.48 | -3.56% |
1 Year | 13.50 | 17.6473 | 11.11 | 14.56 | 72,034 | -0.48 | -3.56% |
3 Years | 13.50 | 17.6473 | 11.11 | 14.56 | 72,034 | -0.48 | -3.56% |
5 Years | 13.50 | 17.6473 | 11.11 | 14.56 | 72,034 | -0.48 | -3.56% |
Skye Bioscience Description
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. It researches and develops and plans to commercialize cannabinoid derivatives through its own directed research efforts and through several license agreements with the University of Mississippi. The company's lead compound, SBI-100, is initially being developed to treat ocular disease. |